Semaglutide FLOW Kidney and Heart Findings: What Patients Should Know 6th June 20266th June 2026 by Living Diabetes Editorial A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
GLP-1 Medicines and Kidney Protection: What the Evidence Shows 6th June 202629th March 2026 by Living Diabetes Editorial Team Some GLP-1 medicines have kidney outcome evidence in type 2 diabetes, but benefits are drug-specific. Learn the practical caveats.
